Negative cost-effectiveness ICER findings on oral GLP-1 semaglutide

4 November 2019

US health technology assessor the Institute for Clinical and Economic Review (ICER) on Friday released an Evidence Report assessing the comparative clinical effectiveness and value of Danish diabetes care giant Novo Nordisk’s (NOV: N) newly-approved oral semaglutide, now trade-named Rybelsus, a GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.

This new therapy is an oral version of the company’s injectable Ozempic, which was approved by the US Food and Drug Administration in 2017. For this analysis, oral semaglutide was compared to background therapy with metformin alone, and to three competitors for add-on therapy: liraglutide (Victoza, Novo Nordisk), sitagliptin (Januvia, Merck [NYSE: MRK]), and empagliflozin (Jardiance, Boehringer Ingelheim).

According to the ICER findings, Rybelsus will be less cost-effective than the comparator drugs. Rybelsus carries a list price of $772.43 for 30-days’ supply, which is on par with comparable injectables.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK